Andrew Burke

Dr Andrew Burke currently works with the UQ Centre for Clinical Research, The University of Queensland and is dual specialist in both infectious diseases and thoracic medicine at The Prince Charles Hospital, Brisbane. He has diverse clinical experience in low income countries and regional Australia and holds a Diploma in Tropical Medicine and Hygiene (Liverpool) and a Masters in Public Health from the University of Queensland. Andrew is a principal investigator on a number of industry lead trials for pulmonary NTM infection. He is an associate investigator on the FORMAT study assessing clinical outcomes in pulmonary Mycobacterium abscessus infection and with Professor Jason Roberts of UQCCR is leading the pharmacokinetic sub-studies in this multi-national trial. Andrew is on the Australian Therapeutic Guidelines writing groups for both antibiotics and respiratory disease. He is current chair of the steering committee of the Australasian Clinical Tuberculosis network (ACTnet) and is on the Queensland Tuberculosis Expert Advisory Group. He is currently undertaking a PhD in the pharmacokinetics of mycobacterial drugs in people with tuberculosis and cystic fibrosis. As part of his PhD he is exploring the role of therapeutic drug montioring in complex mycobacterial infections and sees great potential for Australian and Asia-Pacific researchers to contribute to mycobacterial research through involvement in PK studies. Infectious diseases, thoracic medicine, pulmonary NTM infection, pharmacokinetics of mycobacterial drugs, tuberculosis, cystic fibrosis, therapeutic drug monitoring

[2026] Cutaneous Mycobacterium haemophilum infection in an immunosuppressed host: a case report of diagnostic considerations and microbiologic confirmation [2026] Cerebrospinal Fluid Concentrations of Bedaquiline, Pretomanid, and Linezolid During Curative Treatment of Fluoroquinolone-Resistant Pre–Extensively Drug-Resistant Tuberculous Meningitis [2026] Non-antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis – A systematic review [2026] The Pharmacokinetics & Pharmacodynamics of Antimycobacterial Drugs in People with Cystic Fibrosis and Drug-Resistant Tuberculosis Infection [2026] Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD) [2026] A successful lung transplantation in a patient with ac